The PPMI News page provides updates on the latest PPMI developments, including information on the progress of PD biomarker research, scientific publications and presentations, clinical site and recruitment news, as well as articles in the media that feature the study. Sign up for email updates to be notified when new posts are added.

PPMI News Get updates: Email RSS

Recent Posts

Update: PPMI iPSC Lines

Jun 19, 2017

Cell lines derived from PPMI participants’ PBMCs become available on a rolling basis as they are reprogrammed; some lines are available now. For more information, please email resources@michaeljfox.org. Information about additional tools for PD research – including animal models, antibodies, and assays, can be found on the Michael J. Fox Foundation website.   The Parkinson’s […]

Continue reading...

PPMI at MDS 2017

May 30, 2017

The 21st International Congress of Parkinson’s Disease and Movement Disorders (MDS) conference will take place next week, June 4-8, in Vancouver, Canada. PPMI leadership is happy to announce that several posters will feature PPMI data. We invite you to look for PPMI at this year’s meeting:   Blue Ribbon Highlight:  840 “Multiple modality biomarker prediction […]

Continue reading...

PPMI 2017 Annual Meeting Summary

May 30, 2017

Nearly 180 PPMI investigators, coordinators, study cores, patient advisory and steering committee members, sponsors, and industry partners from around the world met in New York City May 3-4, 2017 to share PPMI study and scientific updates and to discuss the future of the initiative.  The annual meeting remains a critical component to the study. It […]

Continue reading...

PPMI iPSC Lines — A Valuable Tool for Researchers

Mar 23, 2017

The Parkinson’s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]

Continue reading...

Live Webinar February 24: 2016 PPMI Data Challenge Winners

Feb 9, 2017

In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMI’s unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinson’s disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]

Continue reading...

The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson’s Understanding and Study Design

Jun 8, 2016

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]

Continue reading...

2016 PPMI Annual Meeting held in New York City

May 20, 2016

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

Continue reading...

PPMI Q1 2016 Study Update call

Mar 31, 2016

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.

Continue reading...

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Feb 25, 2016

Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Continue reading...

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid ?-synuclein species as surrogate biomarkers for Parkinson’s disease

Feb 15, 2016

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF ?-synuclein species as surrogate biomarkers for Parkinson’s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Continue reading...

 

Tags